The design of a prospective study of pravastatin in the elderly at risk (PROSPER)

The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomized, double-blind, placebo-controlled trial designed to test the hypothesis that treatment with pravastatin will diminish risk of subsequent major vascular events in a cohort of men and women (70 to 82 years old) with...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 1999-11, Vol.84 (10), p.1192-1197
Main Authors: Shepherd, James, Blauw, Gerard Jan, Murphy, Michael B, Cobbe, Stuart M, Bollen, Edward L.E.M, Buckley, Brendan M, Ford, Ian, Jukema, J.Wouter, Hyland, Michael, Gaw, Allan, Lagaay, A.Margot, Perry, Ivan J, Macfarlane, Peter W, Meinders, A.Edo, Sweeney, Brian J, Packard, Chris J, Westendorp, Rudi G.J, Twomey, Cillian, Stott, David J
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cardiology
Cardiovascular disease
Drug therapy
General and cellular metabolism. Vitamins
Medical sciences
Older people
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomized, double-blind, placebo-controlled trial designed to test the hypothesis that treatment with pravastatin will diminish risk of subsequent major vascular events in a cohort of men and women (70 to 82 years old) with preexisting vascular disease or significant risk of developing this condition. Five thousand eight hundred four men and women in addition to receiving advice on diet and smoking, have been randomized equally to treatment with 40 mg pravastatin/day or matching placebo in 3 centers (Cork, Ireland, Glasgow, Scotland, and Leiden, The Netherlands). Following an average 3.5-year intervention period, a primary assessment will be made of the influence of this therapy on major vascular events (a combination of coronary heart disease, death, nonfatal myocardial infarction, and fatal and nonfatal stroke). A number of additional analyses will also be conducted on the individual components of the primary end point, on men, on women, and on subjects with and without previous evidence of vascular disease. Finally, an assessment will be made of the effects of treatment on cognitive function, disability, hospitalization or institutionalization, vascular mortality, and all-cause mortality.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(99)00533-0